Home         Forums  

Go Back   Marrowforums > Treatments > Transfusions and Iron Overload
Register FAQ Search Today's Posts Mark Forums Read

Transfusions and Iron Overload Blood and platelet transfusions, iron testing and treatments

Reply
 
Thread Tools Search this Thread
  #1  
Old Fri Dec 10, 2010, 04:14 PM
akita akita is offline
Member
 
Join Date: Nov 2010
Posts: 110
ASH 2010 Hematologic Responses in MDS Patients - Deferasirox/Exjade

Thanks to Birgittas Link to the abstracts of the ASH 2010 i found a lot of interesting abstracts for "chelation". Maybe is not every abstract interesting for everybody.. Regards, Margarete

---
http://ash.confex.com/ash/2010/webpr...aper28313.html

2912 Hematologic Responses In Myelodysplastic Syndromes (MDS) Patients Treated with Deferasirox: An EPIC Post-Hoc Analysis Using International Working Group (IWG) 2006 Criteria *

Citation: "Improvements in hematologic parameters and/or reductions in transfusion requirements have been associated with iron chelation therapy in transfusion-dependent patients with MDS; however, data has been limited to case reports/small studies"

Now there was a bigger study conducted where 341 iron-overloaded MDS-Patients were enrolled. They were treated with deferasirox.

Citation: "During deferasirox treatment, erythroid responses were observed in 22.6% (63/279) of patients. Median time to response was 113.0 days. Of these erythroid responses, a transfusion reduction-only response with maintenance of Hb level was observed in 10.8% (n=30) of patients, Hb improvement-only response in 10% (n=28) of patients and both transfusion and Hb response observed in 1.8% (n=5) of patients. Platelet and neutrophil responses were observed in 14.0% (n=17) of patients after a median of 169.0 days and 19.6% (n=11) of patients after a median of 226 days, respectively."

"Conclusions: This is the first large study to show that, alongside reducing iron overload, deferasirox may affect hematologic parameters in MDS patients."
__________________
Margarete, 54, living in Vienna, Austria,
MDS/AML M2, diagnosed 9/2007, then Chemos, aSZT 4/2008, chronic GVHD
Reply With Quote
Reply


Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump

Similar Threads
Thread Thread Starter Forum Replies Last Post
Free One-Day AA and MDS Conference in Seattle, June 2010 Marrowforums News and Events 0 Sat May 8, 2010 12:02 PM
Free One-Day MDS Conference in Houston, May 2010 Marrowforums News and Events 0 Fri Apr 16, 2010 02:42 AM
Alemtuzumab (Campath) Effective in MDS BarryB Drugs and Drug Treatments 3 Sun Dec 13, 2009 09:32 AM
Third Canadian MDS Center of Excellence Named Doug Mylie Canada 0 Fri May 16, 2008 09:10 AM
New Oral Medication Gives Hope to Patients with Blood Cancer Doug Mylie Canada 0 Sat Mar 8, 2008 12:27 PM


All times are GMT -4. The time now is 10:26 AM.


Powered by vBulletin® Version 3.6.7
Copyright ©2000 - 2017, Jelsoft Enterprises Ltd.
Forum sites may contain non-authoritative and unverified information.
Medical decisions should be made in consultation with qualified medical professionals.
Site contents exclusive of member posts Copyright 2006-2016 Marrowforums.org